No need to panic, says Serum Institute of India amid concerns over Oxford-Astrazeneca trial error

Buying a Car? See this 7 Benefits of Buying A Used Car

There is this nice feeling that you get when you buy a new vehicle. While for some it could...

DRDO to reopen Medical Facility near Delhi Airport to treat COVID-19 Patients

New Delhi, April 17 : The Defence Research and Development Organisation (DRDO) has decided to reopen a medical facility near...

Amid concerns over the efficacy of Oxford vaccine after pharma major Astrazeneca admitted a dosing error, its India partner Serum Institute of India (SII) said the vaccine candidate is safe and effective and the Indian trials are progressing smoothly with strict adherence to all protocols.

“The AstraZeneca-Oxford vaccine is safe and effective. Even the lowest efficacy results are at 60-70%, making it a viable vaccine against the virus. That said, varied age groups with different dosage forms will result in slight variations and efficacy. We must be patient and not panic,” Pune-based Serum Institute of India said in a statement.

Also Read: AstraZeneca may run additional trial

“The Indian trials are running smoothly with strict adherence to all the necessary processes and protocols. So far, there are no concerns. However, we are going through the data that is available and will make further statement, if needed,” SII said.

Astrazeneca-Oxford vaccine candidate became the third one after Moderna, Pfizer to announce promising results to fight Covid-19. It claimed 70.4 per cent efficacy overall — 90 per cent efficacy in one dosing regimen when the vaccine was given as a half dose, followed by a full dose at least a month later, while another dosing regimen showed 62 per cent efficacy when given as two full doses at least one month apart.

Later, Astrazeneca admitted that the administration of half dose and then a full dose — which showed 90 per cent efficacy — has been actually a dosing error.

As Astrazeneca is planning to run additional trials, Serum Institute of India has said there is yet no reason to worry as far as trials in India are going on.

Prime Minister Narendra Modi on Saturday visit the SII campus to review the mechanism of Covid-19 vaccine production and its distribution.

Disclaimer: This post has not been edited by our staff and is published from a syndicated feed. The Original Source of this post can be found at Source link


Please enter your comment!
Please enter your name here


Coronavirus | Testing sets a record on a day fresh cases touch 2.6 lakh

14.95 lakh samples studied; nearly 1,500 deaths in India as global total reaches 3 million. As many as 14,95,397 samples...

‘Monuments of Sri Mukhalingam deserve World Heritage status’

Some architectural masterpieces created by the rulers of the Eastern Ganga dynasty in the then capital of Kalinga kingdom, Sri Mukhalingam (in Srikakulam district),...

1,212 new cases in Prakasam, Nellore

Three persons succumbed to COVID-19 in SPSR Nellore district even as 1,212 persons tested positive in South Coastal Andhra Pradesh in a span of...

Man risks attack from biker to save dog

The timely intervention of a man saved a dog from the cruel torture of a biker who dragged it along the road at high...

Buying a Car? See this 7 Benefits of Buying A Used...

There is this nice feeling that you get when you buy a new vehicle. While for some it could be something that they are...

More Articles